Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tirofiban Hydrochloride Monohydrate
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Grand Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction
Details : Tirofiban HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Branch Atheromatous Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 05, 2022
Lead Product(s) : Tirofiban Hydrochloride Monohydrate
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Grand Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tirofiban Hydrochloride Monohydrate,Tirofiban,Aspirin,Clopidogrel
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Notably, a non-randomized, case-controlled, investigator sponsored proof of concept study evaluating AGGRASTAT® in combination with standard of care in patients with severe COVID-19 and hypercoagulability found that enhanced platelet inhibition improves...
Product Name : Aggrastat
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 24, 2020
Lead Product(s) : Tirofiban Hydrochloride Monohydrate,Tirofiban,Aspirin,Clopidogrel
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tirofiban Hydrochloride Monohydrate,Tirofiban,Prasugrel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Medicure Announces Top Line Data from FABOLUS-FASTER Trial With AGGRASTAT
Details : The FABOLUS-FASTER trial was designed to assess different regimens of intravenous platelet inhibitors, notably AGGRASTAT® (tirofiban hydrochloride) injection (an IV GP IIb/IIIa inhibitor) and cangrelor (an IV P2Y12 inhibitor) in the early phase of prima...
Product Name : Aggrastat
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 15, 2020
Lead Product(s) : Tirofiban Hydrochloride Monohydrate,Tirofiban,Prasugrel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable